2CB0 Stock Overview
Calithera Biosciences, Inc. operates under a plan of liquidation that was approved in January 2023.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Calithera Biosciences, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$0.06 |
52 Week High | US$4.80 |
52 Week Low | US$0.036 |
Beta | 1.17 |
1 Month Change | 0% |
3 Month Change | 0% |
1 Year Change | -98.19% |
3 Year Change | -99.95% |
5 Year Change | -99.93% |
Change since IPO | -99.96% |
Recent News & Updates
Recent updates
Shareholder Returns
2CB0 | DE Biotechs | DE Market | |
---|---|---|---|
7D | 0% | 2.1% | 1.9% |
1Y | -98.2% | 37.0% | 7.3% |
Return vs Industry: 2CB0 underperformed the German Biotechs industry which returned -23.1% over the past year.
Return vs Market: 2CB0 underperformed the German Market which returned 5.9% over the past year.
Price Volatility
2CB0 volatility | |
---|---|
2CB0 Average Weekly Movement | n/a |
Biotechs Industry Average Movement | 5.8% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 10.1% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 2CB0's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine 2CB0's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2010 | 9 | Susan Molineaux | https://www.calithera.com |
Calithera Biosciences, Inc. operates under a plan of liquidation that was approved in January 2023. Previously, the company was engaged in the clinical stage precision oncology biopharmaceutical business. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.
Calithera Biosciences, Inc. Fundamentals Summary
2CB0 fundamental statistics | |
---|---|
Market cap | €117.18k |
Earnings (TTM) | -€19.62m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs 2CB0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
2CB0 income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$28.53m |
Gross Profit | -US$28.53m |
Other Expenses | -US$7.24m |
Earnings | -US$21.29m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
n/a
Earnings per share (EPS) | -4.37 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0% |
How did 2CB0 perform over the long term?
See historical performance and comparison